Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 132, Issue 6, 2007, Pages 2191-2207

  Parekh, Samir ^a   Anania, Frank A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; CYTOKINE; FATTY ACID; GLUCOSE; INSULIN SENSITIZING AGENT; LEPTIN; METFORMIN; PIOGLITAZONE; RESISTIN; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZOLIDENEDIONE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ARTICLE; BARIATRIC SURGERY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; ENDOPLASMIC RETICULUM; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

EID: 34247863931     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.055     Document Type: Article

References (163)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Falck-Ytter Y., Younossi Z.M., Marchesini G., and McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21 (2001) 17-26
3. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
4. Ruhl C.E., and Everhart J.E. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 8 (2004) 501-519
5. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
6. Daniel S., Ben-Menachem T., Vasudevan G., Ma C.K., and Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 (1999) 3010-3014
7. Franzese A., Vajro P., Argenziano A., Puzziello A., Iannucci M.P., Saviano M.C., Brunetti F., and Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 42 (1997) 1428-1432
8. Tominaga K., Kurata J.H., Chen Y.K., Fujimoto E., Miyagawa S., Abe I., and Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 40 (1995) 2002-2009
9. Angulo P., Keach J.C., Batts K.P., and Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
10. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20 (1989) 594-598
11. Ludwig J., Viggiano T.R., McGill D.B., and Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438
12. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
13. Browning J.D., Kumar K.S., Saboorian M.H., and Thiele D.L. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99 (2004) 292-298
14. Caldwell S.H., Harris D.M., Patrie J.T., and Hespenheide E.E. Is NASH underdiagnosed among African Americans?. Am J Gastroenterol 97 (2002) 1496-1500
15. Solga S.F., Clark J.M., Alkhuraishi A.R., Torbenson M., Tabesh A., Schweitzer M., Diehl A.M., and Magnuson T.H. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 1 (2005) 6-11
16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
17. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., Omatsu T., Nakajima T., Sarui H., Shimazaki M., Kato T., Okuda J., and Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
18. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., and Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
19. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., and Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
20. Silverman J.F., O'Brien K.F., Long S., Leggett N., Khazanie P.G., Pories W.J., Norris H.T., and Caro J.F. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85 (1990) 1349-1355
21. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
22. Ruderman N., Chisholm D., Pi-Sunyer X., and Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 47 (1998) 699-713
23. Jimba S., Nakagami T., Takahashi M., Wakamatsu T., Hirota Y., Iwamoto Y., and Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22 (2005) 1141-1145
24. Poonawala A., Nair S.P., and Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000) 689-692
25. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., and Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53 (2004) 1020-1023
26. Ipekci S.H., Basaranoglu M., and Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 36 (2003) 371
27. Yano E., Tagawa K., Yamaoka K., and Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 54 (2001) 945-951
28. Sorbi D., Boynton J., and Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 94 (1999) 1018-1022
29. Joy D., Thava V.R., and Scott B.B. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol 15 (2003) 539-543
30. Ryan C.K., Johnson L.A., Germin B.I., and Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 8 (2002) 1114-1122
31. Mottin C.C., Moretto M., Padoin A.V., Swarowsky A.M., Toneto M.G., Glock L., and Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 14 (2004) 635-637
32. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., Mullen K.D., Cooper J.N., and Sheridan M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
33. Siegelman E.S., and Rosen M.A. Imaging of hepatic steatosis. Semin Liver Dis 21 (2001) 71-80
34. Skelly M.M., James P.D., and Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 (2001) 195-199
35. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 521-533
36. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., Hall P., Khan M., and George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427
37. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., and Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
38. Contos M.J., Cales W., Sterling R.K., Luketic V.A., Shiffman M.L., Mills A.S., Fisher R.A., Ham J., and Sanyal A.J. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001) 363-373
39. Ong J., Younossi Z.M., Reddy V., Price L.L., Gramlich T., Mayes J., and Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7 (2001) 797-801
40. Adams L.A., Lymp J.F., St. Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., and Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
41. Anagnostopoulos G.K., Arvanitidis D., Tsiakos S., Margantinis G., Grigoriadis K., and Kostopoulos P. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?. J Clin Gastroenterol 37 (2003) 88-89
42. El-Serag H.B., Tran T., and Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004) 460-468
43. Nair S., Mason A., Eason J., Loss G., and Perrillo R.P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36 (2002) 150-155
44. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., Giral P., Grimaldi A., Opolon P., and Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
45. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., and Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 (2002) 1349-1354
46. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., and El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based, case control study. Gut 54 (2005) 533-539
47. Yuan J.M., Govindarajan S., Arakawa K., and Yu M.C. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer 101 (2004) 1009-1017
48. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138
49. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
50. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047
51. Teli M.R., James O.F., Burt A.D., Bennett M.K., and Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995) 1714-1719
52. Silverman J.F., Pories W.J., and Caro J.F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 24 (1989) 275-302
53. Andersen T., Gluud C., Franzmann M.B., and Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 (1991) 224-229
54. Capron J.P., Delamarre J., Dupas J.L., Braillon A., Degott C., and Quenum C. Fasting in obesity: another cause of liver injury with alcoholic hyaline?. Dig Dis Sci 27 (1982) 265-268
55. Hamilton D.L., Vest T.K., Brown B.S., Shah A.N., Menguy R.B., and Chey W.Y. Liver injury with alcoholiclike hyalin after gastroplasty for morbid obesity. Gastroenterology 85 (1983) 722-726
56. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., and Lefebvre P.J. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
57. Requarth J.A., Burchard K.W., Colacchio T.A., Stukel T.A., Mott L.A., Greenberg E.R., and Weismann R.E. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch Surg 130 (1995) 318-325
58. Wang R.T., Koretz R.L., and Yee Jr. H.F. Is weight reduction an effective therapy for nonalcoholic fatty liver?. A systematic review. Am J Med 115 (2003) 554-559
59. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., Torimura T., Inuzuka S., Sata M., and Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 (1997) 103-107
60. American Gastroenterological Association Medical Position Statement: Nonalcoholic Fatty Liver Disease. Gastroenterology 123 (2002) 1702-1704
61. Ioannides-Demos L.L., Proietto J., Tonkin A.M., and McNeil J.J. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 29 (2006) 277-302
62. Foxcroft D.R., and Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 1 (2000) 121-126
63. Harrison S.A., Fincke C., Helinski D., Torgerson S., and Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20 (2004) 623-628
64. Harrison S.A., Ramrakhiani S., Brunt E.M., Anbari M.A., Cortese C., and Bacon B.R. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 98 (2003) 926-930
65. Hatzitolios A., Savopoulos C., Lazaraki G., Sidiropoulos I., Haritanti P., Lefkopoulos A., Karagiannopoulou G., Tzioufa V., and Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 23 (2004) 131-134
66. McMahon F.G., Fujioka K., Singh B.N., Mendel C.M., Rowe E., Rolston K., Johnson F., and Mooradian A.D. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160 (2000) 2185-2191
67. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., Mendels J., Ryan D.H., Schwartz S.L., Scheinbaum M.L., and Seaton T.B. Sibutramine produces dose-related weight loss. Obes Res 7 (1999) 189-198
68. Finer N., Bloom S.R., Frost G.S., Banks L.M., and Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2 (2000) 105-112
69. Finer N., Ryan D.H., Renz C.L., and Hewkin A.C. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 8 (2006) 206-213
70. Sabuncu T., Nazligul Y., Karaoglanoglu M., Ucar E., and Kilic F.B. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 12 (2003) 189-192
71. NIH conference, Consensus Development Conference Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 115 (1991) 956-961
72. Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., and Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
73. Lee W.J., Huang M.T., Wang W., Lin C.M., Chen T.C., and Lai I.R. Effects of obesity surgery on the metabolic syndrome. Arch Surg 139 (2004) 1088-1092
74. Christou N.V., Sampalis J.S., Liberman M., Look D., Auger S., McLean A.P., and MacLean L.D. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 240 (2004) 416-424
75. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
76. Clark J.M., Alkhuraishi A.R., Solga S.F., Alli P., Diehl A.M., and Magnuson T.H. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13 (2005) 1180-1186
77. Mattar S.G., Velcu L.M., Rabinovitz M., Demetris A.J., Krasinskas A.M., Barinas-Mitchell E., Eid G.M., Ramanathan R., Taylor D.S., and Schauer P.R. Surgically induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242 (2005) 610-620
78. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., and Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6 (2000) 998-1003
79. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
80. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., Yesilova Z., Gulsen M., and Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19 (2004) 537-544
81. Nair S., Diehl A.M., Wiseman M., Farr Jr. G.H., and Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20 (2004) 23-28
82. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., and Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 519-525
83. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
84. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., Premkumar A., Park Y., Liang T.J., Yanovski J.A., Kleiner D.E., and Hoofnagle J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
85. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., Stravitz R.T., Shiffman M.L., Clore J., and Mills A.S. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004) 1107-1115
86. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., Tio F., Pulcini J., Berria R., Ma J.Z., Dwivedi S., Havranek R., Fincke C., DeFronzo R., Bannayan G.A., Schenker S., and Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
87. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., and Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
88. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., and Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005) 634-642
89. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., Halavaara J., and Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 (2002) 3023-3028
90. Kahn C.R. Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43 (1994) 1066-1084
91. Sanyal A.J., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
92. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
93. Kim S.P., Ellmerer M., Van Citters G.W., and Bergman R.N. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52 (2003) 2453-2460
94. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velez-Carrasco W., Goldberg I.J., Breslow J.L., and Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98 (2001) 7522-7527
95. Fisher S.J., and Kahn C.R. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 111 (2003) 463-468
96. Tripathy D., Eriksson K.F., Orho-Melander M., Fredriksson J., Ahlqvist G., and Groop L. Parallel manifestation of insulin resistance and β-cell decompensation is compatible with a common defect in type 2 diabetes. Diabetologia 47 (2004) 782-793
97. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., and Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6 (2000) 87-97
98. Nguyen M.T., Satoh H., Favelyukis S., Babendure J.L., Imamura T., Sbodio J.I., Zalevsky J., Dahiyat B.I., Chi N.W., and Olefsky J.M. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280 (2005) 35361-35371
99. Sharma A.M., and Staels B. Peroxisome proliferator-activated receptor γ (PPARγ) and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92 (2007) 386-395
100. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., Greenwood A., Cheng K.H., McLaughlin M., Brown D., Depinho R.A., Wu H., Melton D.A., and Dor Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8 (2005) 185-195
101. Utzschneider K.M., and Kahn S.E. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91 (2006) 4753-4761
102. Miyazaki Y., Glass L., Triplitt C., Wajcberg E., Mandarino L.J., and DeFronzo R.A. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283 (2002) E1135-E1143
103. Reeds D.N., Yarasheski K.E., Fontana L., Cade W.T., Laciny E., DeMoss A., Patterson B.W., Powderly W.G., and Klein S. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 290 (2006) E47-E53
104. Subramanian S., DeRosa M.A., Bernal-Mizrachi C., Laffely N., Cade W.T., Yarasheski K.E., Cryer P.E., and Semenkovich C.F. PPARα activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab 291 (2006) E1365-E1371
105. Begriche K., Igoudjil A., Pessayre D., and Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 (2006) 1-28
106. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., and Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
107. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., and Clore J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
108. Kraegen E.W., Clark P.W., Jenkins A.B., Daley E.A., Chisholm D.J., and Storlien L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40 (1991) 1397-1403
109. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., Romanelli A.J., and Shulman G.I. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 (2004) 32345-32353
110. Wei Y., Wang D., Topczewski F., and Pagliassotti M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 291 (2006) E275-E281
111. Kharroubi I., Ladriere L., Cardozo A.K., Dogusan Z., Cnop M., and Eizirik D.L. Free fatty acids and cytokines induce pancreatic β-cell apoptosis by different mechanisms: role of nuclear factor-κB and endoplasmic reticulum stress. Endocrinology 145 (2004) 5087-5096
112. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., and Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
113. Shi Y., Taylor S.I., Tan S.L., and Sonenberg N. When translation meets metabolism: multiple links to diabetes. Endocr Rev 24 (2003) 91-101
114. Harding H.P., Zhang Y., and Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397 (1999) 271-274
115. Urano F., Wang X., Bertolotti A., Zhang Y., Chung P., Harding H.P., and Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287 (2000) 664-666
116. Harding H.P., Calfon M., Urano F., Novoa I., and Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 18 (2002) 575-599
117. Adams L.A., and Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22 (2005) 1129-1133
118. Pullinger C.R., North J.D., Teng B.B., Rifici V.A., Ronhild de Brito A.E., and Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res 30 (1989) 1065-1077
119. Dashti N., Williams D.L., and Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res 30 (1989) 1365-1373
120. Lewis G.F., Uffelman K.D., Szeto L.W., and Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42 (1993) 833-842
121. Cummings M.H., Watts G.F., Umpleby A.M., Hennessy T.R., Kelly J.M., Jackson N.C., and Sonksen P.H. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 44 (1995) 1059-1065
122. Charlton M., Sreekumar R., Rasmussen D., Lindor K., and Nair K.S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35 (2002) 898-904
123. Tamura S., and Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115 (2005) 1139-1142
124. Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., and Goldstein J.L. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99 (1997) 846-854
125. Yahagi N., Shimano H., Hasty A.H., Matsuzaka T., Ide T., Yoshikawa T., Amemiya-Kudo M., Tomita S., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Osuga J., Harada K., Gotoda T., Nagai R., Ishibashi S., and Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277 (2002) 19353-19357
126. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
127. Wolfrum C., Asilmaz E., Luca E., Friedman J.M., and Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432 (2004) 1027-1032
128. Romano M., Guagnano M.T., Pacini G., Vigneri S., Falco A., Marinopiccoli M., Manigrasso M.R., Basili S., and Davi G. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88 (2003) 5321-5326
129. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280 (2001) E745-E751
130. Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60 (2001) 349-356
131. Ruan H., Miles P.D., Ladd C.M., Ross K., Golub T.R., Olefsky J.M., and Lodish H.F. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-α: implications for insulin resistance. Diabetes 51 (2002) 3176-3188
132. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
133. Muoio D.M., Dohm G.L., Fiedorek Jr. F.T., Tapscott E.B., and Coleman R.A. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 46 (1997) 1360-1363
134. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
135. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., and Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
136. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., and Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
137. Kim Y.B., Uotani S., Pierroz D.D., Flier J.S., and Kahn B.B. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrinology 141 (2000) 2328-2339
138. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (1995) 1263-1271
139. Tartaglia L.A. The leptin receptor. J Biol Chem 272 (1997) 6093-6096
140. Schwartz M.W., Seeley R.J., Campfield L.A., Burn P., and Baskin D.G. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 98 (1996) 1101-1106
141. Zhou Y.T., Shimabukuro M., Koyama K., Lee Y., Wang M.Y., Trieu F., Newgard C.B., and Unger R.H. Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci U S A 94 (1997) 6386-6390
142. Siegrist-Kaiser C.A., Pauli V., Juge-Aubry C.E., Boss O., Pernin A., Chin W.W., Cusin I., Rohner-Jeanrenaud F., Burger A.G., Zapf J., and Meier C.A. Direct effects of leptin on brown and white adipose tissue. J Clin Invest 100 (1997) 2858-2864
143. Potter J.J., Womack L., Mezey E., and Anania F.A. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 244 (1998) 178-182
144. Saxena N.K., Ikeda K., Rockey D.C., Friedman S.L., and Anania F.A. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35 (2002) 762-771
145. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y.J., Lang T., Fukuda T., Yamashina S., Kitamura T., and Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122 (2002) 1399-1410
146. Wunder D., Bersinger N.A., Fux C., Weber R., Bernasconi E., Cavassini M., Bucher H.C., Schiffer V., Schmid P., and Furrer H. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. Aids 19 (2005) 1837-1842
147. Javor E.D., Cochran E.K., Musso C., Young J.R., Depaoli A.M., and Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54 (2005) 1994-2002
148. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., and Lazar M.A. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
149. Steppan C.M., Brown E.J., Wright C.M., Bhat S., Banerjee R.R., Dai C.Y., Enders G.H., Silberg D.G., Wen X., Wu G.D., and Lazar M.A. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 98 (2001) 502-506
150. Rajala M.W., Obici S., Scherer P.E., and Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 111 (2003) 225-230
151. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., Donnini D., Faggian D., Mussap M., Plebani M., Avellini C., Federspil G., Sechi L.A., and Vettor R. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91 (2006) 1081-1086
152. Perseghin G., Lattuada G., De Cobelli F., Ntali G., Esposito A., Burska A., Belloni E., Canu T., Ragogna F., Scifo P., Del Maschio A., and Luzi L. Serum resistin and hepatic fat content in non-diabetic individuals. J Clin Endocrinol Metab 91 (2006) 5122-5125
153. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 30 (2004) 13-19
154. Chen H.C., Jensen D.R., Myers H.M., Eckel R.H., and Farese Jr. R.V. Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 111 (2003) 1715-1722
155. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang Cc C., Itani S.I., Lodish H.F., and Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99 (2002) 16309-16313
156. Shklyaev S., Aslanidi G., Tennant M., Prima V., Kohlbrenner E., Kroutov V., Campbell-Thompson M., Crawford J., Shek E.W., Scarpace P.J., and Zolotukhin S. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A 100 (2003) 14217-14222
157. Baranova A., Gowder S.J., Schlauch K., Elariny H., Collantes R., Afendy A., Ong J.P., Goodman Z., Chandhoke V., and Younossi Z.M. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 16 (2006) 1118-1125
158. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., and Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
159. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
160. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and George J. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology 40 (2004) 46-54
161. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., Gentilcore E., Natale S., Cassader M., Rizzetto M., Pasquali R., and Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
162. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
163. You M., Considine R.V., Leone T.C., Kelly D.P., and Crabb D.W. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42 (2005) 568-577